Last reviewed · How we verify
Delta-4-3-oxosteroid-5-beta-reductase deficiency
Approved treatments
- Cholbam · Mirum
Cholbam works by binding to the G-protein coupled bile acid receptor 1, which helps regulate bile acid levels in the body. - Cholbam · Mirum Pharmaceuticals, Inc.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Delta-4-3-oxosteroid-5-beta-reductase deficiency patent landscape — cliff calendar, originator estates, attackable patents
- Delta-4-3-oxosteroid-5-beta-reductase deficiency treatment landscape brief
- Delta-4-3-oxosteroid-5-beta-reductase deficiency treatment updates RSS
Frequently asked questions about Delta-4-3-oxosteroid-5-beta-reductase deficiency
What drugs treat Delta-4-3-oxosteroid-5-beta-reductase deficiency?
Tracked treatments include Cholbam.
What is the treatment for Delta-4-3-oxosteroid-5-beta-reductase deficiency?
Standard treatment for Delta-4-3-oxosteroid-5-beta-reductase deficiency includes Cholbam. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Delta-4-3-oxosteroid-5-beta-reductase deficiency patent cliff · Delta-4-3-oxosteroid-5-beta-reductase deficiency CI report
- Treatment: Cholbam · Mirum
- Treatment: Cholbam · Mirum Pharmaceuticals, Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing